Clinical Trial
doi: 10.1016/s0140-6736(79)91551-4.
Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone
- PMID: 90215
- DOI: 10.1016/s0140-6736(79)91551-4
Item in Clipboard
Clinical Trial
Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone
Lancet.
.
Abstract
19 patients with Paget's disease were treated orally for 6 months with disodium dichloromethylene diphosphonate. 1600 mg/day (10 patients) significantly reduced urine hydroxyproline, serum alkaline phosphatase, urine calcium, and the number of pagetic bone osteoclasts. Tetracycline double labelling revealed undisturbed bone mineralisation. There was improvement on quantitative bone-scans and bone pain diminished. There was a transient increase in parathyroid hormone level in 13 of the 19 patients during treatment, which was associated with a high serum 1,25 (OH)2D3. No adverse clinical side-effects have been observed and biochemical remission has persisted for 9 months.
Similar articles
-
Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.Adv Exp Med Biol. 1980;128:299-309. doi: 10.1007/978-1-4615-9167-2_35. Adv Exp Med Biol. 1980. PMID: 6448538 No abstract available.
-
Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.Arthritis Rheum. 1980 Oct;23(10):1185-92. doi: 10.1002/art.1780231017. Arthritis Rheum. 1980. PMID: 6448604
-
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.Lancet. 1980 May 17;1(8177):1043-7. doi: 10.1016/s0140-6736(80)91496-8. Lancet. 1980. PMID: 6103389
-
Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).Clin Orthop Relat Res. 1977;(127):94-105. Clin Orthop Relat Res. 1977. PMID: 410576 Review. No abstract available.
-
Treatment of Paget's disease with a diphosphonate (sodium etidronate).Semin Drug Treat. 1972 Summer;2(1):77-81. Semin Drug Treat. 1972. PMID: 4558759 Review. No abstract available.
Cited by
-
Structure-activity relationships of various bisphosphonates.Calcif Tissue Int. 1983;35(1):87-99. doi: 10.1007/BF02405012. Calcif Tissue Int. 1983. PMID: 6839194
-
Increase in fatty acid oxidation in calvaria cells cultured with diphosphonates.Biochem J. 1981 Apr 15;196(1):237-45. doi: 10.1042/bj1960237. Biochem J. 1981. PMID: 6458286 Free PMC article.
-
Paget's disease of bone treated with a five day course of oral tiludronate.Ann Rheum Dis. 1993 Jan;52(1):54-7. doi: 10.1136/ard.52.1.54. Ann Rheum Dis. 1993. PMID: 8427515 Free PMC article. Clinical Trial.
-
Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis.Calcif Tissue Int. 1993 Jun;52(6):407-10. doi: 10.1007/BF00571326. Calcif Tissue Int. 1993. PMID: 8369984 Review. No abstract available.
-
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.Calcif Tissue Int. 1982 Jul;34(4):321-7. doi: 10.1007/BF02411261. Calcif Tissue Int. 1982. PMID: 6814719
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
